https://www.selleckchem.com/pr....oducts/leptomycinb.h
ople with MS as having cognitive impairment secondary to the disease. The paper discusses the potential benefits and drawbacks of the two diagnostic methods, highlighting that more work will be needed in order to establish a standardized and validated method for characterizing these impairments. The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. We recruited 34 persons with multiple sclerosis (MS) under fingolimo
Aimer
Commentaire
Partagez
